NCT04026568

Brief Summary

The purpose of this study is to evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Aug 2021

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 19, 2019

Completed
2.1 years until next milestone

Study Start

First participant enrolled

August 17, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 18, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 18, 2022

Completed
2 months until next milestone

Results Posted

Study results publicly available

September 14, 2022

Completed
Last Updated

October 18, 2022

Status Verified

October 1, 2022

Enrollment Period

11 months

First QC Date

July 17, 2019

Results QC Date

July 28, 2022

Last Update Submit

October 12, 2022

Conditions

Keywords

Peripheral nerve traumalacerationblast injurymangled limb

Outcome Measures

Primary Outcomes (1)

  • Subjective Return of Sensation

    Return of lost sensation after nerve injury attributable to circulating 4-AP. Subjective return of sensation in the injured limb or portion of the limb. Patients for this trial are not able to sense in portions of their limbs. The measure will be sensation, measured on the binary scale of yes or no (able to feel the extremity versus unable to feel) This is assessed through clinical examination of the injured limb.

    During dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury

Study Arms (2)

Single dose 4AP

EXPERIMENTAL

15mm opaque capsule containing 10mg of 4-AP

Drug: 4-Aminopyridine

Placebo

PLACEBO COMPARATOR

Opaque capsule identical looking to the 4AP placebo pill

Drug: Placebo oral tablet

Interventions

Single drug test for nerve continuity

Also known as: oral dalfampridine
Single dose 4AP

Placebo arm

Also known as: Generic placebo
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with trauma involving two or less limbs where the continuity of a given peripheral nerve or nerves is unclear on presenting physical examination.
  • Closed soft tissue envelope obscuring direct observation of the continuity of the affected nerve.
  • Cognitive ability to report sensory and motor deficit during examination.
  • Able to complete dosing within four days (96 hours) of nerve injury diagnosis.
  • Able to provide informed consent
  • Eligible for standard of care plan of monitoring vs surgical exploration of the nerve.
  • Adults subject aged 18-90
  • Known limb trauma which resulted in nerve injury (aim 1) or post-operative/post intervention nerve injury (aim 2).
  • Ability to give written informed consent.
  • Capable of safely undergoing electrodiagnostic testing (EDX).
  • Availability for all testing days and main trial day.

You may not qualify if:

  • Not able to complete dosing within four days (96 hours) of nerve injury diagnosis
  • Distracting injury which prevents adequate examination.
  • Plan for surgical exploration of the nerve during the ensuing 48 hours.
  • Plan for surgical exploration of the nerve as part of another surgical procedure within 48 hours of evaluation.
  • Intoxication during examination or evidence of cognitive deficit that emerges during examination.
  • History of multiple sclerosis, stroke or any other diagnosed neurological disorder
  • History of hypersensitivity to AMPYRA® or 4-aminopyridine
  • Renal impairment based on calculated GFR (GFR\<80 mL/min) This laboratory value is measured in all inpatient trauma patients as part of the standard of care.
  • History of difficult compliance with timely follow up or plan to seek care at another institution closer to home.
  • Patients outside the age range or unable to consent.
  • Patients with a known history of a seizure disorder (4AP overdose can, in selected cases, result in limited seizure activity).
  • Patients with a concomitant traumatic brain injury.
  • Patients unable to communicate return or loss of sensation.
  • Patients unable to exhibit motor control on the affected limb at baseline.
  • Patients unwilling to complete the study requirements.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MS Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

Location

Related Publications (28)

  • Robinson LR. Role of neurophysiologic evaluation in diagnosis. J Am Acad Orthop Surg. 2000 May-Jun;8(3):190-9. doi: 10.5435/00124635-200005000-00006.

    PMID: 10874226BACKGROUND
  • Robinson LR. Traumatic injury to peripheral nerves. Muscle Nerve. 2000 Jun;23(6):863-73. doi: 10.1002/(sici)1097-4598(200006)23:63.0.co;2-0.

    PMID: 10842261BACKGROUND
  • Wilbourn AJ. The electrodiagnostic examination with peripheral nerve injuries. Clin Plast Surg. 2003 Apr;30(2):139-54. doi: 10.1016/s0094-1298(02)00099-8.

    PMID: 12737349BACKGROUND
  • Seddon HJ, Medawar PB, Smith H. Rate of regeneration of peripheral nerves in man. J Physiol. 1943 Sep 30;102(2):191-215. doi: 10.1113/jphysiol.1943.sp004027. No abstract available.

    PMID: 16991601BACKGROUND
  • SEDDON HJ. Nerve grafting. Ann R Coll Surg Engl. 1963 May;32(5):269-80. No abstract available.

    PMID: 13987582BACKGROUND
  • SUNDERLAND S, BRADLEY KC. Denervation atrophy of the distal stump of a severed nerve. J Comp Neurol. 1950 Dec;93(3):401-9. doi: 10.1002/cne.900930304. No abstract available.

    PMID: 14803568BACKGROUND
  • SUNDERLAND S. A classification of peripheral nerve injuries producing loss of function. Brain. 1951 Dec;74(4):491-516. doi: 10.1093/brain/74.4.491. No abstract available.

    PMID: 14895767BACKGROUND
  • Korompilias AV, Lykissas MG, Kostas-Agnantis IP, Vekris MD, Soucacos PN, Beris AE. Approach to radial nerve palsy caused by humerus shaft fracture: is primary exploration necessary? Injury. 2013 Mar;44(3):323-6. doi: 10.1016/j.injury.2013.01.004. Epub 2013 Jan 23.

    PMID: 23352153BACKGROUND
  • Niver GE, Ilyas AM. Management of radial nerve palsy following fractures of the humerus. Orthop Clin North Am. 2013 Jul;44(3):419-24, x. doi: 10.1016/j.ocl.2013.03.012. Epub 2013 Apr 24.

    PMID: 23827843BACKGROUND
  • Li Y, Ning G, Wu Q, Wu Q, Li Y, Feng S. Review of literature of radial nerve injuries associated with humeral fractures-an integrated management strategy. PLoS One. 2013 Nov 8;8(11):e78576. doi: 10.1371/journal.pone.0078576. eCollection 2013.

    PMID: 24250799BACKGROUND
  • Rocchi M, Tarallo L, Mugnai R, Adani R. Humerus shaft fracture complicated by radial nerve palsy: Is surgical exploration necessary? Musculoskelet Surg. 2016 Dec;100(Suppl 1):53-60. doi: 10.1007/s12306-016-0414-3. Epub 2016 Nov 30.

    PMID: 27900704BACKGROUND
  • Han SH, Hong IT, Lee HJ, Lee SJ, Kim U, Kim DW. Primary exploration for radial nerve palsy associated with unstable closed humeral shaft fracture. Ulus Travma Acil Cerrahi Derg. 2017 Sep;23(5):405-409. doi: 10.5505/tjtes.2017.26517.

    PMID: 29052827BACKGROUND
  • Chang G, Ilyas AM. Radial Nerve Palsy After Humeral Shaft Fractures: The Case for Early Exploration and a New Classification to Guide Treatment and Prognosis. Hand Clin. 2018 Feb;34(1):105-112. doi: 10.1016/j.hcl.2017.09.011.

    PMID: 29169591BACKGROUND
  • Perry JD. Electrodiagnosis in musculo-skeletal disease. Best Pract Res Clin Rheumatol. 2005 Jun;19(3):453-66. doi: 10.1016/j.berh.2005.01.007.

    PMID: 15939369BACKGROUND
  • Korte N, Schenk HC, Grothe C, Tipold A, Haastert-Talini K. Evaluation of periodic electrodiagnostic measurements to monitor motor recovery after different peripheral nerve lesions in the rat. Muscle Nerve. 2011 Jul;44(1):63-73. doi: 10.1002/mus.22023.

    PMID: 21674522BACKGROUND
  • Capacio BR, Byers CE, Matthews RL, Chang FC. A method for determining 4-aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. Biomed Chromatogr. 1996 May-Jun;10(3):111-6. doi: 10.1002/(SICI)1099-0801(199605)10:33.0.CO;2-E.

    PMID: 8792860BACKGROUND
  • Elfar JC, Yaseen Z, Stern PJ, Kiefhaber TR. Individual finger sensibility in carpal tunnel syndrome. J Hand Surg Am. 2010 Nov;35(11):1807-12. doi: 10.1016/j.jhsa.2010.08.013.

    PMID: 21050964BACKGROUND
  • Sahin F, Atalay NS, Akkaya N, Ercidogan O, Basakci B, Kuran B. The correlation of neurophysiological findings with clinical and functional status in patients following traumatic nerve injury. J Hand Surg Eur Vol. 2014 Feb;39(2):199-206. doi: 10.1177/1753193413479507. Epub 2013 Mar 1.

    PMID: 23456925BACKGROUND
  • Sims SE, Engel L, Hammert WC, Elfar JC. Hand Sensibility, Strength, and Laxity of High-Level Musicians Compared to Nonmusicians. J Hand Surg Am. 2015 Oct;40(10):1996-2002.e5. doi: 10.1016/j.jhsa.2015.06.009. Epub 2015 Aug 5.

    PMID: 26253604BACKGROUND
  • Chimenti PC, McIntyre AW, Childs SM, Hammert WC, Elfar JC. Prospective cohort study of symptom resolution outside of the ulnar nerve distribution following cubital tunnel release. Hand (N Y). 2015 Jun;10(2):177-83. doi: 10.1007/s11552-014-9688-9.

    PMID: 26034427BACKGROUND
  • Chimenti PC, McIntyre AW, Childs SM, Hammert WC, Elfar JC. Combined Cubital and Carpal Tunnel Release Results in Symptom Resolution Outside of the Median or Ulnar Nerve Distributions. Open Orthop J. 2016 May 24;10:111-9. doi: 10.2174/1874325001610010111. eCollection 2016.

    PMID: 27347239BACKGROUND
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307-10.

    PMID: 2868172BACKGROUND
  • Roberts C. Modelling patterns of agreement for nominal scales. Stat Med. 2008 Mar 15;27(6):810-30. doi: 10.1002/sim.2945.

    PMID: 17634968BACKGROUND
  • Kim J, Farahmand M, Dunn C, Davies Z, Frisbee E, Milla C, Wine JJ. Evaporimeter and Bubble-Imaging Measures of Sweat Gland Secretion Rates. PLoS One. 2016 Oct 21;11(10):e0165254. doi: 10.1371/journal.pone.0165254. eCollection 2016.

    PMID: 27768743BACKGROUND
  • Kiistala R, Kiistala U, Parkkinen MU, Mustakallio KK. Local sweat stimulation with the skin prick technique. Acta Derm Venereol. 1984;64(5):384-8.

    PMID: 6208715BACKGROUND
  • Park SJ, Tamura T. Distribution of evaporation rate on human body surface. Ann Physiol Anthropol. 1992 Nov;11(6):593-609. doi: 10.2114/ahs1983.11.593.

    PMID: 1476561BACKGROUND
  • Buchmann SJ, Penzlin AI, Kubasch ML, Illigens BM, Siepmann T. Assessment of sudomotor function. Clin Auton Res. 2019 Feb;29(1):41-53. doi: 10.1007/s10286-018-0530-2. Epub 2018 May 8.

    PMID: 29737432BACKGROUND
  • Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P, Sipski M, Cohen R, Blight AR. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007 Feb;45(2):158-68. doi: 10.1038/sj.sc.3101947. Epub 2006 Jun 13.

    PMID: 16773037BACKGROUND

Related Links

MeSH Terms

Conditions

LacerationsBlast Injuries

Interventions

4-Aminopyridine

Condition Hierarchy (Ancestors)

Wounds and InjuriesBarotrauma

Intervention Hierarchy (Ancestors)

AminopyridinesAminesOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Limitations and Caveats

The study was terminated early due to lack of funding and the investigator and IND holder leaving the institution.

Results Point of Contact

Title
Kenneth Taylor, MD, Professor of Orthopaedics and Rehabilitation
Organization
Penn State Hershey Medical Center

Study Officials

  • John C Elfar, MD

    Milton S. Hershey Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2019

First Posted

July 19, 2019

Study Start

August 17, 2021

Primary Completion

July 18, 2022

Study Completion

July 18, 2022

Last Updated

October 18, 2022

Results First Posted

September 14, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

The results include both subjective and objective measures. Subjective measures will not be hidden from patients given the nature of measurements. Active discussion of objective measures will wait until final follow up at 20 weeks. Patients can use their subjective assessments in their standard-of-care treatment decisions and with their doctors. Investigators will not inform other physicians except at the consent of patients. Objective test results will not be discussed with treating physicians until 20 weeks. If a patient wants further surgical exploration of an injured peripheral nerve based on subjective return of function (or lack) with members of the study team, a patient conference will be arranged with ethicist and DSMB (Data Safety Monitoring Board). The patient's decision in conjunction with the treating surgeon (not on study team to avoid any conflicts) is to be paramount. Unblinding will also be discussed then with the DSMB.

Locations